Abstract
MUC1 is a high-molecular-weight glycoprotein that is overexpressed in adenocarcinomas and hematological cancers. Numerous preclinical studies in mice have demonstrated that MUC1 is immunogenic, and that cellular and humoral immune responses could be induced depending on the MUC1 vaccine formulation. MUC1-based vaccines have quickly entered into human clinical trials, and immune responses and some clinical responses have been reported. Here, we give an up-to-date review of some of the MUC1-based vaccines that have entered clinical trials and their results in cancer patients.
Financial & competing interests disclosure
This work was supported by a Susan G Komen for Cure project grant (BCTR0600215) (Vasso Apostolopoulos). Vasso Apostolopoulos was an NH&MRC R Douglas Wright Fellow 223316, Choon-Kit Tang was a recipient of a University of Melbourne International Student Scholarship and Maria Katsara a recipient of the Du Pre grant from MSIF. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.